Biotech catalyst strategy - paper portfolio - 2026-10-23 update
📌 Snapshot of the Oct 23, 2026 update (orders for the next open). Always-current page with the full portfolio and daily log →
Updated after the US close of 2026-10-23 · paper trading only, not investment advice · research study
Account value
$982,931
Since start
-1.7%
BIO-EW since start
+2.1%
XBI since start
+2.5%
Cash
81%
Positions
5 / 25
Closed trades
0
| Since start | Book | BIO-EW | XBI | IBB | IWM |
|---|---|---|---|---|---|
| Return | -1.7% | +2.1% | +2.5% | +2.5% | +1.4% |
Rules (pre-registered strategy M, unchanged from the study): every week, US small and mid-cap biotech stocks (SIC 2834/2836/2835/8731, price ≥ $2, market cap $50M-$10B, ≥ $1M daily dollar volume, under $2B revenue) are scanned for an 8-K press release in which the company guides the timing of a clinical-trial readout ("topline data expected in Q1 2027"). Stocks whose guided window starts 40-100 weekdays ahead are ranked nearest first and the top 5 are bought at the next open, 4% of the account each (max 5% of the stock's daily dollar volume), up to 25 positions; idle money stays in cash. Each stock is sold at the open 3 weekdays before its readout window starts (the date planned at purchase), or at the next open after the company files an 8-K with topline results, an FDA approval, a complete response letter or a clinical hold - the trade is a pre-readout run-up, not a bet on the binary outcome. No stop-loss. Costs 0.75% per side under $2B market cap, 0.25% above. Data: SEC EDGAR 8-K full-text search + XBRL, Massive prices.
Honest caveats. The research study FAILED its own pass bar: from 2012 to 2026 the strategy beat the equal-weight biotech universe (BIO-EW) in every test period but lost to the XBI ETF in the 2023-26 holdout (11.9% vs 16.9% a year) and in most years; the gains came from a few big trades and from the candidate set rather than the ranking. This paper book tests whether the edge over equal-weight biotech persists live. Pre-stated review on 2028-10-19 (2 years): keep it only if it beats BIO-EW by at least 3 points a year after costs and is not worse than XBI by more than 5 points a year. The 8-K classifier misses some readouts, so some positions will still be holding when the binary result comes out.
Orders for the next open
Buy - this week's picks (signals of 2026-10-23; 36 candidates among 266 eligible biotechs)
| Ticker | Company | Close | Readout window | Planned sell | Source (8-K sentence) |
|---|---|---|---|---|---|
| ANNX | Annexon, Inc. | $3.75 | 2027-01-01 – 2027-03-31 | 2026-12-29 | Following this assessment, the DMC may recommend that the ARCHER II overall study has met its Month 15 primary endpoint, enabling the planned analysis of the trial’s two sub-studies, with results anticipated in the first quarter of 2027; or it may recommend that the study continues until the Month 24 primary endpoint analysis. 8-K 2026-08-12 |
| PTGX | Protagonist Therapeutics, Inc | $138.43 | 2027-01-01 – 2027-03-31 | 2026-12-29 | PN-881 (oral IL-17 antagonist peptide): Pharmacokinetic data from the Phase 1 study supports the decision to advance PN-881 into a comprehensive Phase 2 psoriasis program, with initiation expected in early Q1 2027. 8-K 2026-08-05 |
| ANRO | Alto Neuroscience, Inc. | $21.97 | 2027-01-01 – 2027-06-30 | 2026-12-29 | • Topline data remain expected in 1H 2027 for the ALTO-300 Phase 2b MDD trial and mid-2027 for the ALTO-100 Phase 2b BPD trial. 8-K 2026-08-12 |
| RNAC | Cartesian Therapeutics, Inc. | $6.18 | 2027-01-01 – 2027-03-31 | 2026-12-29 | Topline data from Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis expected in 1Q27 8-K 2026-09-29 |
| ORKA | Oruka Therapeutics, Inc. | $80.15 | 2027-01-01 – 2027-03-31 | 2026-12-29 | The Company now expects to report Week 16 data from ORCA-SURGE, a Phase 2 trial in moderate-to-severe PsO, in the first quarter of 2027. 8-K 2026-08-10 |
Sell: none
Open positions (5)
| Ticker | Bought | Value | Return | Readout window | Planned sell | Source |
|---|---|---|---|---|---|---|
| PEPG | 2026-10-19 | $39,233 | -1.2% | 2027-01-01 – 2027-06-30 | 2026-12-29 | Results from the 12.5 mg/kg cohort are expected in the first half of 2027, at which time PepGen plans to engage with regulators in an end of Phase 2 meeting to discuss plans for the registrational program. 8-K |
| ZURA | 2026-10-19 | $34,116 | -14.1% | 2027-01-01 – 2027-06-30 | 2026-12-29 | • TibuSURE enrollment complete, exceeding initial enrollment target with 91 participants randomized in SSc; topline data expected H1 2027 8-K |
| OLMA | 2026-10-19 | $38,095 | -4.0% | 2027-01-01 – 2027-03-31 | 2026-12-29 | • Completed enrollment in the pivotal Phase 3 OPERA-01 trial; top-line data are now expected in the first quarter of 2027 8-K |
| ORKA | 2026-10-19 | $44,171 | +10.7% | 2027-01-01 – 2027-03-31 | 2026-12-29 | The Company now expects to report Week 16 data from ORCA-SURGE, a Phase 2 trial in moderate-to-severe PsO, in the first quarter of 2027. 8-K |
| MGNX | 2026-10-19 | $27,317 | -31.2% | 2027-01-01 – 2027-06-30 | 2026-12-29 | The Company anticipates completing enrollment of these 20 patients by year-end 2026 and reporting updated study results in the first half of 2027. 8-K |
Daily log
| US close | Account | Return | BIO-EW | XBI | Cash | Pos. |
|---|---|---|---|---|---|---|
| 2026-10-23 | $982,931 | -1.7% | +2.1% | +2.5% | 81% | 5 |
| No trades | ||||||
| 2026-10-22 | $1,008,390 | +0.8% | +4.7% | +3.9% | 79% | 5 |
| No trades | ||||||
| 2026-10-21 | $1,013,809 | +1.4% | +4.9% | +4.7% | 79% | 5 |
| No trades | ||||||
| 2026-10-20 | $1,014,341 | +1.4% | +5.5% | +5.0% | 79% | 5 |
| No trades | ||||||
| 2026-10-19 | $1,004,450 | +0.4% | +1.0% | +1.4% | 80% | 5 |
| Bought 5: PEPG, ZURA, OLMA, ORKA, MGNX | ||||||
Claude picks vs random picks
Claude book (test): the same candidates, slot size, 25-position cap, exits and costs as the main book; only the selection differs. Every weekend each of the week's candidates gets a dossier (8-K guidance and press releases, current ClinicalTrials.gov records, recent papers, cash runway, offerings, other catalysts) and one Claude analysis (strongest available model, web search only) that estimates the chance the stock beats the equal-weight biotech basket by the planned sell date (p_runup), the chance of a binary event before it (p_early_shock) and a 0-100 score; the top 5 scores are bought. Scores are frozen before the Monday open. The main book's tie-order picks are effectively random within the same candidate set (the study found M's ranking no better than random), so this is Claude picks vs 5 random picks.
| Book | Account | Return | vs BIO-EW | vs XBI | Closed trades | Hit rate | Positions |
|---|---|---|---|---|---|---|---|
| Main book: 5 tie-order (random) picks | $982,931 | -1.7% | -3.8% | -4.2% | 0 | - | 5 |
| Claude book: Claude's top 5 | $1,000,295 | +0.0% | -2.0% | -2.5% | 0 | - | 5 |
Hit rate = share of closed trades with a positive return after costs. vs BIO-EW / XBI = return difference in points since the start (2026-10-19 open).
Claude's top 5 for the signals of 2026-10-23 (36 of 36 candidates scored; frozen 2026-10-23 19:55 New York time). Main-book picks this week: ANNX, PTGX, ANRO, RNAC, ORKA.
| # | Ticker | Score | p_runup | p_early_shock | Planned sell | Key reasons (Claude) |
|---|---|---|---|---|---|---|
| 1 | LBRX | 58 | 56% | 7% | 2026-12-29 | • This is a classic pre-readout setup. Topline data from NOVA-2, the pivotal Phase 3 trial of LB-102 in schizophrenia, was moved up to 1H 2027 from 2H 2027 because enrollment ran faster than expected. The holding period ends just … • An in-person and virtual R&D Day on 2026-10-27, the day after entry, will cover LB-102's mechanism and the Phase 3 program, with KOL Roger McIntyre presenting. A Piper Sandler management meeting follows on 2026-10-29. Both are … • Dilution risk is low. Cash was $327.8M at 2026-06-30, the company also raised a $150M private placement at $34.94 from top-tier biotech funds, and guided runway runs beyond Q2 2029. A follow-on offering before the readout looks … |
| 2 | RNAC ★ | 56 | 55% | 12% | 2026-12-29 | • Fact: the Phase 3 AURORA topline for Descartes-08 in myasthenia gravis is guided to 1Q27 and was restated on 2026-09-29 alongside the retreatment data. The holding period ends just before the window opens. That makes this a … • Fact: enrollment is complete (128 actual, ACTIVE_NOT_RECRUITING). The primary completion date is estimated at 2026-12-30 and the primary endpoint is at Month 4. Topline before 2026-12-29 is therefore unlikely, so the risk of an … • Fact: cash was about $149.3M at 2026-06-30. Runway guidance is into 2028, backed by a $150M K2 HealthVentures credit facility ($50M drawn May 2026). That lowers the chance of a large offering before the readout. However, an ATM … |
| 3 | MGNX | 56 | 55% | 42% | 2026-12-29 | • Fact: the stock closed at $2.25 on 2026-10-23, down about 38% in one session after the company called its interim Phase 1 MGC026 results at ESMO 'positive' (27% best response rate in head-and-neck cancer, 29% confirmed response … • Fact: market cap is about $143M against pro forma cash of about $327-328M (Q2 press release 2026-08-13, and Citizens on 2026-07-27, who saw a 30% discount to cash when the stock was $3.70). The company guides cash runway through … • Fact: the company guided preliminary MGC028 (ADAM9 ADC) dose-escalation results for 'late 2026'. Judgement: there is a reasonable chance this lands inside the holding period (through 2026-12-29) as an interim data event, and it … |
| 4 | TECX | 55 | 54% | 13% | 2026-12-29 | • Classic pre-readout setup: APEX Phase 2 (n=191, PH-HFpEF) fully enrolled June 2026, IDMC recommended continuation July 2026, topline guided to 'early Q1 2027'; the holding period ends 3 trading days before that window, so … • Stock is heavily de-rated into the catalyst: $20.07, -47% from 52-week high, -30% over 60d, below 50-dma ($28.33) and 200-dma ($29.61); fell ~22% in September despite positive TX2100 Phase 1a data on 2026-09-29. Negative momentum … • Balance sheet is strong: $227.1M cash at 2026-06-30, runway guided into Q1 2029 (38 months by TTM burn), so a large dilutive offering before the readout is unlikely; however the company did sell ~$11.7M via ATM in Q2 2026, so … |
| 5 | QURE | 54 | 55% | 45% | 2026-12-29 | • Stock has collapsed ~60%+ since the 2026-09-29 48-month AMT-130 update (cUHDRS 44% slowing, p=0.144, not significant vs 80% at 36 months); at $22.43 it is -68% from the 52-week high and 20d return is -41%. Capitulation setup … • Major procedural FDA event falls inside the holding period: BLA submitted 2026-09-02 with priority review requested; 60-day filing decision is due ~early November 2026. FDA had aligned at the June 2026 Type B meeting that … • The 48-month data were NOT part of the BLA (based on 36-month analysis); company attributes the weaker 48-month result to survivor bias in the Enroll-HD external control (53% control dropout). The FDA could still request/consider … |
★ = also a main-book pick this week. Claude's reasons are model output with web search; they can be wrong.
Pre-stated review. 12-month check (2027-10-18): among all candidates whose planned holding window has ended, Claude's top-quintile scores (within each week) vs bottom-quintile scores, realised abnormal return = stock open-to-open from the buy day to the planned sell day minus BIO-EW over the same window; t-statistic with standard errors clustered by signal week. 24-month check (2028-10-19): the Claude book must beat the main book by at least 3 points a year after costs to be worth keeping. Calibration: p_runup vs the realised share of candidates that beat BIO-EW.
Quintile test: no completed holding windows yet (0 weeks so far; the first planned sell dates are at the end of December 2026).
Calibration table (p_runup vs realised): appears once the first holding windows have ended.
Shadow book V1 (test)
Shadow book V1 (tracked, not the real book): the same rules, but any scheduled catalyst counts - 8-K readout timing guidance, a PDUFA date or an FDA advisory committee meeting 40-100 weekdays ahead - and only topline-result 8-Ks trigger an early sale. In the study V1 beat M in 2020-22 and 2023-26, but that was found after the fact, so M stays the real book.
Shadow account
$1,002,858
vs real book
+2.03%
Shadow max drawdown
-0.3%
Closed trades
0
Holds (5): ANAB, COGT, MLYS, PRAX, VNDA
Next open - buy: MLYS (pdufa 2026-12-22), PRAX (pdufa 2026-12-27), COGT (pdufa 2026-12-30), ANNX (timing 2027-01-01), PTGX (timing 2027-01-01); sell: none
Research (price-only, 2012-2026, after costs): strategy M 15.1% a year 2012-19 vs BIO-EW 11.2% and XBI 20.1%; 2020-22 0.0% vs BIO-EW -12.4% and XBI -4.3%; 2023-26 11.9% vs BIO-EW 5.8% and XBI 16.9%; max drawdown about -47%. Without its 10 best trades each period was roughly flat or negative. (BIO-EW figures corrected 2026-10-23: the earlier benchmark held no stocks in 13 months because of a data bug; on the pre-set 2-year-window score M was no better than BIO-EW in 2023-26.) BIO-EW = equal weight of every eligible stock, rebalanced monthly with the same costs (here from the first open of the book). Not investment advice.
6 redactions applied (6 cards).
- cards: 6
Published via wiis. Originals are encrypted at rest; this page reflects the redacted version. report abuse.
Discussion
No comments yet.